Glancy Binkow & Goldberg LLP, representing investors of Amarin Corporation plc (“Amarin” or the “Company”) (NASDAQ:AMRN), has filed a class action lawsuit in the United States District Court for the Southern District of New York on behalf of a class (the “Class”) comprising all persons who purchased the common stock, call options or sold put options of Amarin between July 9, 2009 and October 15, 2013 (the “Class Period”). Members of the foregoing Class have until January 3, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.

A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW & GOLDBERG LLP. PLEASE CONTACT US AT (212) 682-5340, TOLL-FREE AT (888) 773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM TO DISCUSS THIS MATTER OR IF YOU PURCHASED AMARIN SECURITIES PRIOR TO THE CLASS PERIOD. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.

Amarin is a biopharmaceutical company, focused on the development and commercialization of therapeutic products for the treatment for cardiovascular diseases. The Company’s lead product Vascepa is an adjunct to diet to reduce triglyceride levels in adult patients and also for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol (the “Anchor” indication).

The Complaint alleges that defendants issued materially misleading statements concerning Amarin’s business, operations and financial prospects. Specifically, the Complaint alleges that:

• Defendants misrepresented the prospects for Food and Drug Administration approval of Vascepa for the ANCHOR indication.
• Defendants failed to disclose that the FDA had informed Amarin that there was a lack of prospective, controlled clinical trial data demonstrating that pharmaceutical reduction of triglycerides significantly reduces residual cardiovascular risk.

If you are a member of the Class described above, you may move the Court no later than January 3, 2014, to serve as lead plaintiff; however, you must meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.

To learn more about this action, or if you purchased Amarin securities prior to the Class Period and have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.